The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Isatuximab + VRd or VCd in newly diagnosed transplant-ineligible myeloma
Enrique M. Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, presents updates from a Phase Ib study of isatuximab, bortezomib, cyclophosphamide and dexamethasone (VCd) or lenalidomide and dexamethasone (VRd) in transplant-ineligible newly diagnosed multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
